Amwill Health Care Ltd

Amwill Health Care Limited was originally incorporated on August 21, 2017 under the name Amwill Health Care Private Limited', dated August 22, 2017 issued by the Deputy Registrar of Companies, Karnataka at Bangalore. Further, Company was converted into a Public Limited Company and a fresh Certificate of Incorporation dated January 25, 2024 was issued by the Registrar of Companies, Karnataka at Bangalore with the change in name to Amwill Health Care Limited'. Amwill Health Care is a derma-cosmetic development company, associated with contract manufacturers, distributor and third party product development agencies, which has enabled in developing capabilities, in manufacturing, packaging and distribution. Since inception, the focus has been on developing formulations which offer solutions to various dermatological disorders. The product profile of Company is divided into two categories, development and contract manufacturing of generic dermatological solutions; and developing and formulating solutions to specific dermatological problem. Majority of products marketed by them, were developed by Promoter, Anand Gandhi, in the capacity of a sole proprietor of M/s. Amwill Healthcare. The Company registered the first transaction of sale of cosmetic products in the year 2020. It launched a new product under the name XL-HYDRA', a face moisturiser and launched a new formulation in hair-care therapy under the name- Fin-XL Pro Gel' in a gel based formulation in 2021. In order to formalise the business of M/s. Amwill Healthcare and to widen the reach of its products, Promoters formed the Company and executed a Memorandum of Understanding dated March 31, 2020 with M/s. Amwill Healthcare and the Company, where intellectual property rights, on the products developed by our Promoters under M/s. Amwill Healthcare were transferred to the Company in 2021. The Company has created a structured storage and distribution chain through one of its promoter group entities, M/s. Amderma Healthcare LLP, which was established under the guidance of Tarun Gandhi. It entered into a carrying and forwarding agreement dated May 15, 2024 effective from January 1, 2024, with Amderma, for appointing Amderma as a Carrying and Forwarding Agent. The Company came up with IPO of 54,03,600 equity shares of Rs 10 each by raising funds aggregating to Rs 59.98 crore consisting a fresh issue of 44,03,600 equity shares amounting to Rs 48.88 crore and 10,00,000 equity shares amounting to Rs 11.10 crores through offer for sale on February 7, 2025.